News >

FDA Grants Fast Track Designation to ARV-110 for mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, May 29, 2019

John Houston, PhD

John Houston, PhD

The FDA has granted a fast track designation to ARV-110, a PROTAC® protein degrader, for use as a treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have disease progression following ≥2 systemic therapies.

 
Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer. Arvinas, Inc. Published May 29, 2019. https://bit.ly/2wrTs44. Accessed May 29, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x